Last updated on April 2018

Phase III Radium 223 mCRPC-PEACE III

Brief description of study

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Clinical Study Identifier: NCT02194842

Find a site near you

Start Over

AZ Turnhout

Turnhout, Belgium
  Connect »


Copenhagen, Denmark
  Connect »


Bern, Switzerland
  Connect »

Gustave Roussy

Villejuif, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.